Antineoplastic

Antineoplastics
Tabine series
2-Deoxy-D-ribose [intermediate]
2-Fluoroadenosine [HOT] [intermediate]
Zomib series
(R)-BoroLeu-(+)-Pinanediol-CF3COOH [HOT] [intermediate]

 

 

 

 

 

Doxorubicin hydrochloride,25316-40-9
Adriamycin Hydrochloride
Doxorubicin hydrochloride,25316-40-9,Antineoplastic Antibiotics
CAS
25316-40-9
Molecular Formula
C27H29NO11.ClH
Molecular Weight
579.983
Systematic Name
Doxorubicin hydrochloride
Assay
USP35
Certificate of analysis
Doxorubicin hydrochloride,25316-40-9
View via PDF file
Doxorubicin hydrochloride,25316-40-9,Antineoplastic Antibiotics
Specification
Items
Specification
Test result
Appearance
Orange red powder
Complies
Identification
IR
Complies
M.P
198-203℃
198.3-199.5℃
Crystallinity
Meets the requirements
Complies
Water
<4.0%
1.4%
Residue on ignition
<0.1%
0.05%
Heavy metals
<0.001%
Complies
Limit of solvent residues
Acetone:<0.5%
Complies
total of acetone and alcohol:<2.5%
Complies
Total impurities
<2.0%
1.5%
pH
4.5-5.5
5.2
Solubility
Soluble in water,in isotonic sodium
chloride solution and in methanol,
practically insoluble in chloroform, in ether and in other organic solvents
Complies
Assay
98.0%-102.0%
99.5%
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

Packing
Doxorubicin hydrochloride,25316-40-9
Packing 1
1g
Packing 2
10g
   
   
   
Bulk request
sales@lanospharma.com
Related Antineoplastic Antibiotics
   
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product(Doxorubicin hydrochloride,25316-40-9,Antineoplastic Antibiotics).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.